Research programme: nucleic acid therapeutics - Marina Biotech

Drug Profile

Research programme: nucleic acid therapeutics - Marina Biotech

Alternative Names: Duchenne muscular dystrophy therapeutics - Marina Biotech; Myotnoic dystrophy therapeutics - Marina Biotech; Rare disease therapeutics - Marina Biotech

Latest Information Update: 20 May 2016

Price : $50

At a glance

  • Originator Marina Biotech
  • Class Antisense RNA; MicroRNAs; Nucleic acids
  • Mechanism of Action Nucleic acid modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Duchenne muscular dystrophy; Myotonic dystrophy

Most Recent Events

  • 02 May 2016 Microlin Bio terminates its plans to acquire nucleic acid therapeutics assets
  • 01 Mar 2016 Microlin Bio plans to acquire nucleic acid therapeutics assets
  • 17 Feb 2016 Preclinical trials in Duchenne muscular dystrophy in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top